Stefanie Kulnigg-Dabsch
Stefanie Kulnigg-Dabsch has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Christoph Gasche
Division of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria
3 shared publications Clemens Dejaco
Medical University of Vienna Department of Internal Medicine III, Division of Gastroenterology and Hepatology Vienna
2 shared publications- Jürgen Stein
DGD Kliniken Frankfurt Sachsenhausen
2 shared publications - Adrian Frick
Medical University of Vienna Department of Internal Medicine III, Division of Gastroenterology and Hepatology Vienna
1 shared publication Alexander Moschen
Universitätsklinik für Innere Medizin 2, Johannes Kepler Universität Linz, Linz, Austria
1 shared publicationAnton Stift
Klinische Abteilung für Viszeralchirurgie, Universitätsklinik für Allgemeinchirurgie, Medizinische Universität Wien, Vienna, Austria
1 shared publication
Latest Publications
- Open Access
- 19 June 2026
- Published by Oxford University Press (OUP) in Crohn's & Colitis 360
- Vol. 8 (2) , otag064
Stoma formation and associated risk factors in patients with Crohn′s disease in an Austrian tertiary referral hospital: A retrospective explorative study of long-term follow-up
Background: The cumulative probability of patients with Crohn’s disease (CD) requiring a stoma at a tertiary center is unknown. We sought to evaluate the time to stoma formation after diagnosis as well as risk factors for stoma formation in CD patients. Methods: This is a retrospective, longitudinal cohort study on consecutive patients with CD at an Austrian tertiary referral university center. In brief, patients with CD were identified and disease-specific data were captured prior to June 2023. The probability of stoma-free survival by subgroups of various potential risk factors was assessed by means of Kaplan-Meier estimates (Log-rank test). Results: Of 1267 CD patients, 142 (11.2%) underwent a stoma formation (80 ileostomies, 62 colostomies), of which 51 (35.9%) were permanent stomas. The probability of stoma-free survival at 10 and 20 years after diagnosis was 92% and 86%, respectively. Ileocolonic and colonic location, penetrating behavior, and perianal disease were associated with a higher risk for stoma formation (each p < 0.001). If these risk factors coincided, the probability of stoma-free survival at 10 and 20 years after diagnosis was only 76.4% and 67.2%, respectively. Patients diagnosed from 2000 onwards had a trend for a lower stoma risk than patients diagnosed earlier (p = 0.084). Conclusions: The coincidence of colonic or ileocolonic involvement, penetrating behaviour and perianal fistulas significantly reduced the probability of stoma-free survival to 68% 20 years after diagnosis. Identification of these risk factors for stoma formation may help identify patients at risk and thus raise awareness for this group.
- 19 June 2026
- Published by Oxford University Press (OUP) in Crohn's & Colitis 360
- Vol. 8 (2) , otag064
Open AccessStoma formation and associated risk factors in patients with Crohn′s disease in an Austrian tertiary referral hospital: A retrospective explorative study of long-term follow-up
Background: The cumulative probability of patients with Crohn’s disease (CD) requiring a stoma at a tertiary center is unknown. We sought to evaluate the time to stoma formation after diagnosis as well as risk factors for stoma formation in CD patients. Methods: This is a retrospective, longitudinal cohort study on consecutive patients with CD at an Austrian tertiary referral university center. In brief, patients with CD were identified and disease-specific data were captured prior to June 2023. The probability of stoma-free survival by subgroups of various potential risk factors was assessed by means of Kaplan-Meier estimates (Log-rank test). Results: Of 1267 CD patients, 142 (11.2%) underwent a stoma formation (80 ileostomies, 62 colostomies), of which 51 (35.9%) were permanent stomas. The probability of stoma-free survival at 10 and 20 years after diagnosis was 92% and 86%, respectively. Ileocolonic and colonic location, penetrating behavior, and perianal disease were associated with a higher risk for stoma formation (each p < 0.001). If these risk factors coincided, the probability of stoma-free survival at 10 and 20 years after diagnosis was only 76.4% and 67.2%, respectively. Patients diagnosed from 2000 onwards had a trend for a lower stoma risk than patients diagnosed earlier (p = 0.084). Conclusions: The coincidence of colonic or ileocolonic involvement, penetrating behaviour and perianal fistulas significantly reduced the probability of stoma-free survival to 68% 20 years after diagnosis. Identification of these risk factors for stoma formation may help identify patients at risk and thus raise awareness for this group.
- Open Access
- 22 April 2025
- Published by Georg Thieme Verlag KG in Zeitschrift für Gastroenterologie
- Vol. 63 (05) , 502-511
Leitfaden Kurzdarmsyndrom
Zusammenfassung: Das Kurzdarmsyndrom ist ein seltenes und komplexes Krankheitsbild, das meist aufgrund von ausgeprägter Dünndarmresektionen entsteht und zu einem chronischen Darmversagen führen kann. Durch die verminderte intestinale Resorptionsoberfläche kommt es zu einer reduzierten Aufnahme von Makro-, Mikronährstoffen und/oder Flüssigkeit. Dementsprechend entstehen vielfältige Symptome wie Durchfall, Gewichtsverlust, Vitaminmangelerscheinungen, Niereninsuffizienz, Hepatopathie und andere mit großem Effekt auf die Lebensqualität dieser Patienten. Die Therapie dieser Patienten ist komplex und bedarf einer interdisziplinären Zusammenarbeit von verschiedenen Fachdisziplinen wie Diätologie, Gastroenterologie, Chirurgie sowie die zusätzliche engmaschige Betreuung im niedergelassenen Bereich. Oft brauchen Patienten eine dauerhafte (heim-)parenterale Unterstützung. Therapien müssen individuell entschieden und regelmäßig auf Effektivität und Nebenwirkungen überprüft werden. Weiter sind regelmäßige Bestimmungen verschiedener klinischer und laborchemischer Parameter notwendig. Die Morbidität und Mortalität dieser Erkrankung ist hoch und vom Auftreten von Komplikationen geprägt. Dieser Leitfaden soll einen Überblick über die Erkrankung sowie die notwendige Diagnostik und Therapieoptionen geben und die bestmögliche Betreuung dieser komplexen Patienten ermöglichen.
- 22 April 2025
- Published by Georg Thieme Verlag KG in Zeitschrift für Gastroenterologie
- Vol. 63 (05) , 502-511
Open AccessLeitfaden Kurzdarmsyndrom
Zusammenfassung: Das Kurzdarmsyndrom ist ein seltenes und komplexes Krankheitsbild, das meist aufgrund von ausgeprägter Dünndarmresektionen entsteht und zu einem chronischen Darmversagen führen kann. Durch die verminderte intestinale Resorptionsoberfläche kommt es zu einer reduzierten Aufnahme von Makro-, Mikronährstoffen und/oder Flüssigkeit. Dementsprechend entstehen vielfältige Symptome wie Durchfall, Gewichtsverlust, Vitaminmangelerscheinungen, Niereninsuffizienz, Hepatopathie und andere mit großem Effekt auf die Lebensqualität dieser Patienten. Die Therapie dieser Patienten ist komplex und bedarf einer interdisziplinären Zusammenarbeit von verschiedenen Fachdisziplinen wie Diätologie, Gastroenterologie, Chirurgie sowie die zusätzliche engmaschige Betreuung im niedergelassenen Bereich. Oft brauchen Patienten eine dauerhafte (heim-)parenterale Unterstützung. Therapien müssen individuell entschieden und regelmäßig auf Effektivität und Nebenwirkungen überprüft werden. Weiter sind regelmäßige Bestimmungen verschiedener klinischer und laborchemischer Parameter notwendig. Die Morbidität und Mortalität dieser Erkrankung ist hoch und vom Auftreten von Komplikationen geprägt. Dieser Leitfaden soll einen Überblick über die Erkrankung sowie die notwendige Diagnostik und Therapieoptionen geben und die bestmögliche Betreuung dieser komplexen Patienten ermöglichen.
- Open Access
- 26 September 2016
- Published by Springer Nature in Wiener Medizinische Wochenschrift
- Vol. 166 (13-14) , 424-430
Autoimmune gastritis
Summary Autoimmune gastritis is a chronic inflammatory disease with destruction of parietal cells of the corpus and fundus of the stomach. The known consequence is vitamin B12 deficiency and, consequently, pernicious anemia. However, loss of parietal cells reduces secretion of gastric acid which is also required for absorption of inorganic iron; thus, iron deficiency is commonly found in patients with autoimmune gastritis. This usually precedes vitamin B12 deficiency and is found mainly in young women. Patients with chronic iron deficiency, especially those refractory to oral iron therapy, should therefore be evaluated for the presence of autoimmune gastritis.
- 26 September 2016
- Published by Springer Nature in Wiener Medizinische Wochenschrift
- Vol. 166 (13-14) , 424-430
Open AccessAutoimmune gastritis
Summary Autoimmune gastritis is a chronic inflammatory disease with destruction of parietal cells of the corpus and fundus of the stomach. The known consequence is vitamin B12 deficiency and, consequently, pernicious anemia. However, loss of parietal cells reduces secretion of gastric acid which is also required for absorption of inorganic iron; thus, iron deficiency is commonly found in patients with autoimmune gastritis. This usually precedes vitamin B12 deficiency and is found mainly in young women. Patients with chronic iron deficiency, especially those refractory to oral iron therapy, should therefore be evaluated for the presence of autoimmune gastritis.
- Open Access
- 12 December 2014
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 60 (5) , 1375-1381
Clinical Significance of C-Reactive Protein Levels in Predicting Responsiveness to Iron Therapy in Patients with Inflammatory Bowel Disease and Iron Deficiency Anemia
Background Iron deficiency anemia (IDA) is a common complication of inflammatory bowel disease (IBD). In clinical practice, many patients receive initial treatment with iron tablets although intravenous (i.v.) iron supplementation is often preferable. Aim This study investigated whether systemic inflammation at initiation of treatment (assessed by C-reactive protein [CRP] and interleukin-6 [IL-6] measurements) predicts response to iron therapy. Methods Data from a previously published phase III trial were retrospectively analyzed after stratification of patients according to baseline CRP (>4 vs. ≤4 mg/L) and IL-6 (>6 vs. ≤6 pg/mL) levels. The study population consisted of patients with Crohn’s disease or ulcerative colitis and IDA (Hb ≤ 110 g/L and TSAT < 20 % or serum ferritin < 100 ng/mL), randomized to either oral (ferrous sulfate) or i.v. iron (ferric carboxymaltose). Results A total of 196 patients were evaluated (oral iron: n = 60; i.v. iron: n = 136). Baseline CRP and IL-6 levels were independent of patients’ initial Hb levels and iron status (serum ferritin and TSAT; all p > 0.05). Among iron tablet-treated patients, Hb increase was significantly smaller in the high- versus low-CRP subgroup (1.1 vs. 2.0, 2.3 vs. 3.1, and 3.0 vs. 4.0 g/dL at weeks 2, 4, and 8, respectively; all p < 0.05). Differences were less pronounced with stratification according to baseline IL-6. Response to i.v. iron was mainly independent of inflammation. Conclusions Patients with high baseline CRP achieved a lower Hb response with oral iron therapy. Our results suggest that CRP may be useful to identify IBD patients who can benefit from first-line treatment with i.v. iron to improve their IDA.
- 12 December 2014
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 60 (5) , 1375-1381
Open AccessClinical Significance of C-Reactive Protein Levels in Predicting Responsiveness to Iron Therapy in Patients with Inflammatory Bowel Disease and Iron Deficiency Anemia
Background Iron deficiency anemia (IDA) is a common complication of inflammatory bowel disease (IBD). In clinical practice, many patients receive initial treatment with iron tablets although intravenous (i.v.) iron supplementation is often preferable. Aim This study investigated whether systemic inflammation at initiation of treatment (assessed by C-reactive protein [CRP] and interleukin-6 [IL-6] measurements) predicts response to iron therapy. Methods Data from a previously published phase III trial were retrospectively analyzed after stratification of patients according to baseline CRP (>4 vs. ≤4 mg/L) and IL-6 (>6 vs. ≤6 pg/mL) levels. The study population consisted of patients with Crohn’s disease or ulcerative colitis and IDA (Hb ≤ 110 g/L and TSAT < 20 % or serum ferritin < 100 ng/mL), randomized to either oral (ferrous sulfate) or i.v. iron (ferric carboxymaltose). Results A total of 196 patients were evaluated (oral iron: n = 60; i.v. iron: n = 136). Baseline CRP and IL-6 levels were independent of patients’ initial Hb levels and iron status (serum ferritin and TSAT; all p > 0.05). Among iron tablet-treated patients, Hb increase was significantly smaller in the high- versus low-CRP subgroup (1.1 vs. 2.0, 2.3 vs. 3.1, and 3.0 vs. 4.0 g/dL at weeks 2, 4, and 8, respectively; all p < 0.05). Differences were less pronounced with stratification according to baseline IL-6. Response to i.v. iron was mainly independent of inflammation. Conclusions Patients with high baseline CRP achieved a lower Hb response with oral iron therapy. Our results suggest that CRP may be useful to identify IBD patients who can benefit from first-line treatment with i.v. iron to improve their IDA.
- 1 October 2013
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 19 (11) , E85-E86
Reply to Zuo et al.
- 1 October 2013
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 19 (11) , E85-E86
Reply to Zuo et al.